Start of 2016:
1) Major accounting discrepancies hit the media. It starts as a small whistleblower investigation, and eventually makes its' way to CNBC and Wall Street Journal. Merck will be caught red-handed cooking the books, Enron style. Investors were lied to for several straight quarters.
2) Last few half-functional remnants of MRL R&D sold off in their entirety to Chinese outfits, as Merck corporate struggles desperately to prop up their short-term cash reserves. The 1 or 2 "gems" left in the MRL pipeline are then tested on Chinese death-row prisoners. Candidate compounds prematurely execute 20% of the prisoners dosed.
3) Frasier, Perlmutter, and Kellogg all retire within a 2 month period.
4) Accounting scandal continues to grow. Merck files for Chapter 11, while simultaneously announcing a 40% layoff of the already skeletal workforce.
5) Peter Kim resurfaces to write an editorial in the New York Times. He blasts the "interpretation" of the Chinese death-row study (#3 above). "In reality, only 18% of the prisoners died due to the sold-off MRL compounds", he writes. "When taken as directed, these compounds are an important therapeutic regimen in the management of chronic pain. The stupor and subsequent coma they induce is highly effective at mitigating the pain signals these patients experienced previously".
6) End of 2016: Following Foxconn's example, Merck erects catch-nets above sidewalks of its' remaining buildings, to mitigate the 5-fold increase in employees jumping to their deaths. Foxconn sues Merck for catch-net patent infringement. Ken Frasier comes out of recent retirement to head up Merck's catch-net defense.
7) Merck sends Holiday greetings to its remaining employees. Everyone gets a "Be Well" coffee mug and a year's supply of Kool-Aid. Happy 2017!